Ono Pharmaceutical Co., Ltd. (TYO:4528)
2,368.00
-20.00 (-0.84%)
Jul 1, 2026, 3:30 PM JST
Ono Pharmaceutical Employees
Ono Pharmaceutical had 4,206 employees as of March 31, 2026. The number of employees decreased by 81 or -1.89% compared to the previous year.
Employees
4,206
Change (1Y)
-81
Growth (1Y)
-1.89%
Revenue / Employee
122.63M JPY
Profits / Employee
16.59M JPY
Market Cap
1.12T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 4,206 | -81 | -1.89% |
| Mar 31, 2025 | 4,287 | 434 | 11.26% |
| Mar 31, 2024 | 3,853 | 92 | 2.45% |
| Mar 31, 2023 | 3,761 | 74 | 2.01% |
| Mar 31, 2022 | 3,687 | 80 | 2.22% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Otsuka Holdings | 37,758 |
| Daiichi Sankyo Company | 20,171 |
| Astellas Pharma | 14,099 |
| Kyowa Kirin | 5,161 |
| Chugai Pharmaceutical | 5,104 |
| Santen Pharmaceutical | 3,968 |
| JCR Pharmaceuticals | 987 |
| Perseus Proteomics | 32 |
Ono Pharmaceutical News
- 4 weeks ago - Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting - Business Wire
- 7 weeks ago - Ono Pharmaceutical Quarterly report: Q4 2026 - Filings
- 7 weeks ago - Ono Pharmaceutical Slides: Q4 2026 - Filings
- 2 months ago - Ono Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting - Business Wire
- 3 months ago - Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan - Business Wire
- 3 months ago - Ono Pharmaceutical Slides: Investor presentation - Filings
- 4 months ago - Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology - Business Wire
- 4 months ago - Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL - Business Wire